Literature DB >> 25217571

Peripheral nerve and neuromuscular junction pathology in Pompe disease.

Darin J Falk1, Adrian Gary Todd2, Sooyeon Lee3, Meghan S Soustek2, Mai K ElMallah4, David D Fuller5, Lucia Notterpek3, Barry J Byrne1.   

Abstract

Pompe disease is a systemic metabolic disorder characterized by lack of acid-alpha glucosidase (GAA) resulting in ubiquitous lysosomal glycogen accumulation. Respiratory and ambulatory dysfunction are prominent features in patients with Pompe yet the mechanism defining the development of muscle weakness is currently unclear. Transgenic animal models of Pompe disease mirroring the patient phenotype have been invaluable in mechanistic and therapeutic study. Here, we demonstrate significant pathological alterations at neuromuscular junctions (NMJs) of the diaphragm and tibialis anterior muscle as prominent features of disease pathology in Gaa knockout mice. Postsynaptic defects including increased motor endplate area and fragmentation were readily observed in Gaa(-/-) but not wild-type mice. Presynaptic neuropathic changes were also evident, as demonstrated by significant reduction in the levels of neurofilament proteins, and alterations in axonal fiber diameter and myelin thickness within the sciatic and phrenic nerves. Our data suggest the loss of NMJ integrity is a primary contributor to the decline in respiratory and ambulatory function in Pompe and arises from both pre- and postsynaptic pathology. These observations highlight the importance of systemic phenotype correction, specifically restoration of GAA to skeletal muscle and the nervous system for treatment of Pompe disease.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25217571      PMCID: PMC4291243          DOI: 10.1093/hmg/ddu476

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  56 in total

1.  Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.

Authors:  Benjamin L Farah; Lauran Madden; Songtao Li; Sierra Nance; Andrew Bird; Nenad Bursac; Paul M Yen; Sarah P Young; Dwight D Koeberl
Journal:  FASEB J       Date:  2014-01-21       Impact factor: 5.191

2.  Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I).

Authors:  Friedrich Metzger; Waseem Sajid; Stefanie Saenger; Christian Staudenmaier; Chris van der Poel; Bettina Sobottka; Angelika Schuler; Mandy Sawitzky; Raphael Poirier; Dietrich Tuerck; Eginhard Schick; Andreas Schaubmar; Friederike Hesse; Kurt Amrein; Hansruedi Loetscher; Gordon S Lynch; Andreas Hoeflich; Pierre De Meyts; Hans-Joachim Schoenfeld
Journal:  J Biol Chem       Date:  2011-04-01       Impact factor: 5.157

3.  Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9.

Authors:  Mai K ElMallah; Darin J Falk; Michael A Lane; Thomas J Conlon; Kun-Ze Lee; Nadeem I Shafi; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Hum Gene Ther Methods       Date:  2012-04       Impact factor: 2.396

Review 4.  Structure of the neuromuscular junction: function and cooperative mechanisms in the synapse.

Authors:  Masaharu Takamori
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

5.  Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease.

Authors:  Darin J Falk; Cathryn S Mah; Meghan S Soustek; Kun-Ze Lee; Mai K Elmallah; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454

Review 6.  At the "junction" of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression.

Authors:  B B Goulet; R Kothary; R J Parks
Journal:  Curr Mol Med       Date:  2013-08       Impact factor: 2.222

7.  Shared resistance to aging and ALS in neuromuscular junctions of specific muscles.

Authors:  Gregorio Valdez; Juan C Tapia; Jeff W Lichtman; Michael A Fox; Joshua R Sanes
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

Review 8.  Centronuclear (myotubular) myopathy.

Authors:  Heinz Jungbluth; Carina Wallgren-Pettersson; Jocelyn Laporte
Journal:  Orphanet J Rare Dis       Date:  2008-09-25       Impact factor: 4.123

Review 9.  Non-muscle involvement in late-onset glycogenosis II.

Authors:  Massimiliano Filosto; Alice Todeschini; Maria Sofia Cotelli; Valentina Vielmi; Fabrizio Rinaldi; Silvia Rota; Mauro Scarpelli; Alessandro Padovani
Journal:  Acta Myol       Date:  2013-10

10.  Distinct changes in synaptic protein composition at neuromuscular junctions of extraocular muscles versus limb muscles of ALS donors.

Authors:  Jing-Xia Liu; Thomas Brännström; Peter M Andersen; Fatima Pedrosa-Domellöf
Journal:  PLoS One       Date:  2013-02-26       Impact factor: 3.240

View more
  35 in total

1.  Long-term exercise-specific neuroprotection in spinal muscular atrophy-like mice.

Authors:  Farah Chali; Céline Desseille; Léo Houdebine; Evelyne Benoit; Thaïs Rouquet; Bruno Bariohay; Philippe Lopes; Julien Branchu; Bruno Della Gaspera; Claude Pariset; Christophe Chanoine; Frédéric Charbonnier; Olivier Biondi
Journal:  J Physiol       Date:  2016-02-27       Impact factor: 5.182

2.  Therapeutic Benefit of Autophagy Modulation in Pompe Disease.

Authors:  Jeong-A Lim; Baodong Sun; Rosa Puertollano; Nina Raben
Journal:  Mol Ther       Date:  2018-05-03       Impact factor: 11.454

3.  Synaptic failure: The achilles tendon of sphingolipidoses.

Authors:  Ludovico Cantuti-Castelvetri; Ernesto R Bongarzone
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

4.  Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning.

Authors:  Manuela Corti; Brian Cleaver; Nathalie Clément; Thomas J Conlon; Kaitlyn J Faris; Gensheng Wang; Janet Benson; Alice F Tarantal; Davis Fuller; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2015-09       Impact factor: 5.032

5.  Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.

Authors:  Adrian G Todd; Jessica A McElroy; Robert W Grange; David D Fuller; Glenn A Walter; Barry J Byrne; Darin J Falk
Journal:  Ann Neurol       Date:  2015-06-30       Impact factor: 10.422

Review 6.  Progress and challenges of gene therapy for Pompe disease.

Authors:  Giuseppe Ronzitti; Fanny Collaud; Pascal Laforet; Federico Mingozzi
Journal:  Ann Transl Med       Date:  2019-07

7.  Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.

Authors:  Jin Su; Alexandra Sherman; Phillip A Doerfler; Barry J Byrne; Roland W Herzog; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2015-06-05       Impact factor: 9.803

Review 8.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

9.  Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.

Authors:  Allison M Keeler; Marina Zieger; Sophia H Todeasa; Angela L McCall; Jennifer C Gifford; Samantha Birsak; Sourav R Choudhury; Barry J Byrne; Miguel Sena-Esteves; Mai K ElMallah
Journal:  Hum Gene Ther       Date:  2018-07-25       Impact factor: 5.695

10.  A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice.

Authors:  Ni-Chung Lee; Wuh-Liang Hwu; Shin-Ichi Muramatsu; Darin J Falk; Barry J Byrne; Chia-Hao Cheng; Nien-Chu Shih; Kai-Ling Chang; Li-Kai Tsai; Yin-Hsiu Chien
Journal:  Mol Neurobiol       Date:  2017-09-11       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.